Drug class
Purine antimetabolite; thiopurine immunosuppressant and antineoplastic agent
Mechanism of action
Converted intracellularly to thioguanine nucleotides and other active metabolites that interfere with purine nucleotide synthesis and incorporation into DNA and RNA, suppressing proliferation of rapidly dividing lymphoid cells.
General use cases
- Treatment of acute lymphoblastic leukaemia (ALL) as part of combination chemotherapy, including maintenance regimens; dose and use are specialist-directed and depend on TPMT/NUDT15 status and blood-count monitoring
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
